Novo Nordisk's Two-Front Battle: A Pill That's Selling vs. A Pipeline Under Siege
Published on 08/05/2026 at 11:30 | Redaktion boerse-global.de
Investors in Novo Nordisk are being pulled in opposite directions at once. The Danish pharma giant's oral weight-loss drug is flying off pharmacy counters in the US, yet the company's shares remain pinned near multi-month lows, caught between a legal escalation, a failed heart-drug study, and intensifying competition from Eli Lilly.
The stock's recent trading tells the story of a market struggling to price in two very different realities. After a bruising week that saw the shares shed 14.80 percent in just seven sessions — including a 5.85 percent drop on Tuesday that closed the stock at 38.44 euro — the shares rebounded Wednesday to 39.69 euro. Still, that leaves the equity roughly 28 percent below its 52-week high of 54.86 euro, a level touched as recently as January.
A Legal Cloud That Won't Lift
The latest overhang traces back to a US federal judge's decision this week to allow parts of a shareholder lawsuit to proceed to discovery. Investors have alleged that Novo's statements about CagriSema's tolerability and the design of its late-stage trial may have been misleading. The ruling is not a finding of guilt — it merely opens the door to evidence-gathering — but it guarantees the CagriSema saga will dominate headlines for months, possibly well into 2027. A company spokesperson dismissed the claims as unfounded and vowed a vigorous defense.
The lawsuit's roots lie in February, when CagriSema patients lost an average of 20.2 percent of their body weight in trials — short of the non-inferiority bar set by Eli Lilly's Tirzepatid, which delivered 23.6 percent. CEO Mike Doustdar has pushed back on that reading, telling CNBC the market punished the data too harshly and that additional studies would paint a fuller picture.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Pill That Keeps Delivering
Amid the legal noise, the commercial story has quietly improved. The oral version of Wegovy has racked up more than 5 million US prescriptions since its January launch, capturing roughly a third of all new prescriptions in the weight-loss category. That momentum helped lift adjusted revenue by 7 percent at constant exchange rates in the second quarter.
The company has responded by raising its 2026 guidance. Instead of the previously forecast 4 to 12 percent decline in sales and profit growth at constant currencies, Novo now expects a range of 0 to minus 6 percent.
A European rollout is next: following European Commission approval in July, the oral formulation is slated to launch across the EU in the second half of the year. Management is also integrating three former Catalent production sites, a move aimed at easing the supply constraints that have long plagued the injectable portfolio.
The Bill Comes Due
The optimism has limits. Novo took an extraordinary writedown of 6.3 billion Danish kroner, with 4 billion tied to the pipeline candidate Monlunabant. That charge coincides with the failure of the Phase 3 ZEUS program in cardiovascular disease — a setback announced July 31 that helped trigger last week's selloff.
The financial damage is visible in the numbers. Adjusted operating profit fell 16 percent at constant exchange rates in the second quarter. Eli Lilly's oral competitor Orforglipron reached the US market in April and has already contributed to a 4 percent decline in adjusted revenue in the first quarter. Meanwhile, CagriSema's path to approval remains uncertain: the REDEFINE-1 study showed 22.7 percent weight loss, but mixed data from other trials and a still-pending FDA decision — submitted in late 2025 — cloud the outlook for what was supposed to be the next blockbuster.
Reading the Charts
Technical indicators suggest the stock is approaching a decision point. The 14-day RSI sits at 33.6, near oversold territory, while the distance to the 200-day moving average has narrowed to just 1.55 percent — a zone that has historically attracted buyers. The annualized volatility of 38.33 percent reflects just how jittery trading has become.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
For bulls, support at the 100-day moving average of 38.01 euro should hold as long as the oral Wegovy prescription trend persists and the European launch gains traction. A sustained break above the 50-day average at 40.98 euro would signal the market has digested the writedown and the ZEUS disappointment.
For bears, the risks are equally clear. Should Eli Lilly keep gaining share or the FDA demand additional CagriSema data, a retest of the 52-week low at 30.25 euro comes into play. The next catalysts: regulatory news on CagriSema and interim data from the remaining Ziltivekimab studies, HERMES and ARTEMIS, expected in early 2027.
What makes this moment unusual isn't any single data point — pharma stocks routinely swing 5 percent on trial results. It's the compounding effect: a clinical failure that shook pipeline confidence, a legal proceeding that could keep the uncertainty alive for years, and a competitor that keeps taking share. That combination weighs heavier than any single missed quarter, and it explains why a stock with a genuinely successful product launch still can't find its footing.
Ad
Novo Nordisk Stock: New Analysis - 5 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
